Patients with prostate cancer who will start treatment with enzalutamide within label
Patients who are on treatment with opioids and/or therapeutic anticoagulation, that are treated with or willing and able to switch to morphine (2 dd extended release equivalent dose) and/or edoxaban (30mg or 60mg OD, according to the label)
Age at least 18 years
Patients who are able and willing to give written informed consent prior to screening
Patients from whom it is possible to collect blood samples
Life expectancy of \> 3 months
Stable renal function and renal clearance \> 50ml/min
You may not be if
Patients who are co-treated with drugs that could interfere with the metabolism of enzalutamide, edoxaban and/or morphine
Clareo Health | Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
